EU5 Cervical Cancer Market Insights, Epidemiology and Market Forecasts 2016-2023 – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Cervical
Cancer-Market Insights, Epidemiology and Market Forecast – 2023 – EU5″
drug pipelines to their offering.
The therapeutic market size of Cervical Cancer in European (EU5) market
is expected to grow at a Compound Annual Growth Rate of 0.019% and reach
up to USD 109.8 million by 2023.
The global market size of prophylaxis treatment for Cervical Cancer is
expected to grow at a Compound Annual Growth Rate of 0.71% and reach up
to USD 2210.9 Million by 2023.
Cervical Cancer needs to be focused more and more because it adversely
affects younger women. It is the fourth most common cause of death among
women. Cervical Cancer occurs due to the uncontrolled growth of healthy
cells in cervix and forms cervical lesions. It spreads to other tissues
such as vagina and uterus. Cervical Cancer is caused by inheritance of
defects or mutation in genes.
Cervical cancer is also caused due to the infection by the Human
Papilloma Virus (HPV) which can infect cells on the surface of the skin
and those lining the genitals, anus, mouth and throat, but not the blood
or internal organs such as the heart or lungs.
Key Topics Covered:
- Report Introduction
- Cervical Cancer Disease Overview
- Diagnosis of Cervical Cancer
- Epidemiology and Patient Population of Cervical Cancer
- United Kingdom (UK)
- Germany (GE)
- Italy (IT)
- France (FR)
- Spain (SP)
- Treatment Landscape
- Treatment Algorithm
- Treatment by Stages
- Cervical Cancer Treatment Regimens
- Current Unmet Needs
- Cervical Cancer Emerging therapies Market Size
- Pipeline Product Analysis
- Cervical Cancer Therapeutics Market in Europe
- Cervical Cancer Prophylaxis Treatment Global
- Market Drivers
- Market Barriers
- Appendix
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/zkss6s/cervical
Contacts
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Cervical
Cancer Drugs